{
  "docId": "019de075-6448-707d-82ec-cbbeebb7feb3",
  "docSlug": "1eef6abd03697885c8a70f789c554a37",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 23,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a split-column layout to contrast the completed Phase 1a with the active Phase 1b.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-6448-707d-82ec-cbbeebb7feb3/12",
  "deckHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3",
  "deckJsonHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3.json",
  "deckAnchorHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Initial Phase 1b Data Read-Out Expected in 1Q2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee6a7120-a6a5-4fb3-ba18-334ee4b9bee5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.96,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "diagram",
      "text": "Phase 1a vs Phase 1b comparison",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "220352d3-fee5-4f59-a8f5-00458baf5ae0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Clinicaltrials.gov NCT05226507",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11e94e5e-9a8e-482e-8917-c59eb98c38a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Enrolling patients with platinum-resistant, ARID1A-mutated ovarian cancer (target population)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e60b17ae-37ac-4aef-9347-620717983f18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.3,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "a. Fast Track Designation granted for platinum resistant, ARID1A-mutated ovarian carcinoma,",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f67558d-896b-4b6c-b282-f88fab65dd4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXP800: Phase 1b Underway, Fast Track Designation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65e97232-7adb-4c5f-9a9a-5e60c12f03e9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "4205aac2-273e-492f-9fed-c280ac46dcc1",
      "evidence": "The slide compares sequential clinical trial phases (1a and 1b) and provides a future milestone date.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 12,
      "beatId": "c3c10501-d1a0-41bf-bc7e-a2ae6a6ffd40",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck mentions the market opportunity for NXP800 and NXP900.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}